Highly efficient and high throughput screening platforms and top quality are critical for the development of novel antibodies with high affinity, specificity and desired target profile. In alphamab, we have invested extensively in the naive fully human antibody library, Ig-like scaffold library, and Immunized nanobody library (camel). With state of art hage and yeast display platforms, high quality hits can be rapidly generated.
